Effect of Outpatient Treatment of Febrile Neutropenia on the Risk Threshold for the Use of CSF in Patients with Cancer Treated with Chemotherapy

This publication has 18 references indexed in Scilit:

• Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis
  The American Journal of Medicine, 2002
• Clinical Practice and Future Needs in Recombinant Human Granulocyte Colony-Stimulating Factor Treatment: A Review of Randomized Trials in Clinical Haemato-Oncology
  Journal of International Medical Research, 2001
• A Predictive Model for Neutropenia Associated with Cancer Chemotherapy
  Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2000
• The economics of febrile neutropenia: implications for the use of colony-stimulating factors
  European Journal Of Cancer, 1998
• Economie impact of granulopoiesis stimulating agents on the management of febrile neutropenia
  Current Opinion in Oncology, 1998
• Filgrastim (r-metHuG-CSF): the first 10 years
  Blood, 1996
• American Society of Clinical Oncology guidelines for the clinical use of hematopoietic colony-stimulating factors
  Current Opinion in Hematology, 1996
• Decision Analysis of Hematopoietic Growth Factor Use in Patients Receiving Cancer Chemotherapy
  JNCI Journal of the National Cancer Institute, 1993
• Hematopoietic Growth Factors
  New England Journal of Medicine, 1989
• A Randomized Trial Comparing Ceftazidime Alone with Combination Antibiotic Therapy in Cancer Patients with Fever and Neutropenia
  New England Journal of Medicine, 1986